
Orthocell shares OCC.AX rise 7.2% to A$1.260
Fourth top performer in ASX All Ordinaries Index .AORD
Regenerative medicine company reports June quarter revenue of A$2.73 mln ($1.79 mln), up 22.8% Q/Q and 48.4% Y/Y
Revenue driven by sales of flagship nerve repair product, Remplir, in Australia
U.S. sales of Remplir not included in June quarter revenue numbers; expects U.S. sales to ramp up during 1H26
($1 = 1.5225 Australian dollars)